Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi（新）
GUSD（纯图）
Rewards

Eli Lilly's Obesity Drug Retratrutide Shows 20.8%–22.6% Weight Loss in Phase 3 Trials

GateNews
Stocks
According to CNBC, on July 23, Eli Lilly announced positive results from two Phase 3 clinical trials of retratrutide, a once-weekly obesity treatment. In diabetic patients, retratrutide reduced body weight by up to 20.8% at week 80, with meaningful improvements in key blood glucose markers. In adults with severe obesity and cardiovascular disease, average weight loss reached 22.6% over the same period, with significant reductions in major cardiovascular risk factors. The company adjusted its regulatory submission timeline to Q1 2027 to complete manufacturing and quality data validation. Eli Lilly shares closed up 1.97% on July 23.
View Source
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

8h ago
ETH rises slightly by 0.44% in 15 minutes: market pressure and an overbought pullback converge
10h ago
ETH drops sharply by 0.56% in 15 minutes: Key resistance levels trigger technical sell pressure, and the order book shows a heavy sell-side advantage—leading to a sharp short-term plunge
13h ago
ETH 15-minute pullback of 0.63%: A short-term adjustment triggered by selling pressure from TBO resistance and rising BTC dominance in sync
15h ago
ETH is up slightly by 0.53% over the past 15 minutes: technical resistance is holding it back, compounded by rising BTC dominance that suppresses near-term performance
In-Depth Analysis

Eli Lilly Delays Retatrutide Obesity Drug Filing to Q1 2027 After Trial Success

Lucas Bennett17h ago

Bitcoin Climbs Above $65,800 as ETFs Record Sixth Consecutive Inflow Day

Crypto Frontier22h ago

Kolon TissueGene Stocks Hit 3-Day Limit-Down After US Phase 3 Trial Failure

Lucas Bennett22h ago
Comment
0/400
No comments